All research
Human randomized trial / 2014
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation
Stanley TL, Feldpausch MN, Oh J, et al.
Study overview
A six-month, double-blind trial randomized 50 adults with HIV receiving antiretroviral treatment. Imaging showed reductions in visceral and liver fat in the tesamorelin group compared with placebo.
Results are specific to the study. This is an editorial summary, not personal treatment advice.
Study limitations
This was a small, specific population. Imaging changes are not proof of general weight-loss benefit or long-term clinical outcomes. Early glucose changes were observed.
About this summary
This summary uses the cited abstract and bibliographic record. Read the original methods and results for the full context.